Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma

References

• Zheng -P-P, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 2018;23:1175–13. doi:10.1016/j.drudis.2018.02.012.
   PubMed Web of Science ®Google Scholar
• Milone MC, Bhoj VG. The pharmacology of T cell therapies. Mol Ther Methods Clin Dev. 2018;8:210–221. doi:10.1016/j.omtm.2018.01.010.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219–1226. doi:10.1158/2159-8290.CD-18-0442.
   PubMed Web of Science ®Google Scholar
• Siegler EL, Wang P. Preclinical models in chimeric antigen receptor-engineered T-cell therapy. Hum Gene Ther. 2018;29:534–546. doi:10.1089/hum.2017.243.
   PubMed Web of Science ®Google Scholar
• Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, et al. Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the society for immunotherapy of cancer. J ImmunoTher Cancer. 2017;5:77. doi:10.1186/s40425-017-0278-6.
   PubMed Web of Science ®Google Scholar
• Aresu L. Canine lymphoma, more than a morphological diagnosis: what we have learned about diffuse large B-cell lymphoma. Front Vet Sci. 2016;3:77. doi:10.3389/fvets.2016.00077.
   PubMed Web of Science ®Google Scholar
• Childress MO, Ramos-Vara JA, Ruple A. Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma. Vet Comp Oncol. 2018;16:E159–68. doi:10.1111/vco.12364.
   PubMed Web of Science ®Google Scholar
• Zandvliet M. Canine lymphoma: a review. Vet Q. 2016;36:76–104. doi:10.1080/01652176.2016.1152633.
   PubMed Web of Science ®Google Scholar
• Richards KL, Motsinger-Reif AA, Chen H-W, Fedoriw Y, Fan C, Nielsen DM, Small GW, Thomas R, Smith C, Dave SS, et al. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res. 2013;73:5029–5039. doi:10.1158/0008-5472.CAN-12-3546.
   PubMed Web of Science ®Google Scholar
• Rao S, Lana S, Eickhoff J, Marcus E, Avery PR, Morley PS, Avery AC. Class II major histocompatibility complex expression and cell size independently predict survival in canine B-cell lymphoma. J Vet Internal Med. 2011;25:1097–1105. doi:10.1111/j.1939-1676.2011.0767.x.
   PubMed Web of Science ®Google Scholar
• Jubala CM, Wojcieszyn JW, Valli VEO, Getzy DM, Fosmire SP, Coffey D, Bellgrau D, Modiano JF. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet Pathol. 2005;42:468–476. doi:10.1354/vp.42-4-468.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12–23. doi:10.1038/nrclinonc.2013.197.
   PubMed Web of Science ®Google Scholar
• Atherton MJ, Morris JS, McDermott MR, Lichty BD. Cancer immunology and canine malignant melanoma: A comparative review. Vet Immunol Immunopathol. 2016;169:15–26. doi:10.1016/j.vetimm.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer. Trends Mol Med. 2011;17:380–388. doi:10.1016/j.molmed.2011.02.004.
   PubMed Web of Science ®Google Scholar
• LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, et al. Perspectives from man’s best friend: national academy of medicine’s workshop on comparative oncology. Sci Transl Med. 2016;8:324ps5–324ps5. doi:10.1126/scitranslmed.aaf0746.
   PubMed Web of Science ®Google Scholar
• Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, O’Connor CM, Powell DJ, Mason NJ. Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Mol Ther. 2016;24:1602–1614. doi:10.1038/mt.2016.146.
   PubMed Web of Science ®Google Scholar
• Marcucci KT, Jadlowsky JK, Hwang W-T, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, et al. Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients. Mol Ther. 2018;26:269–279. doi:10.1016/j.ymthe.2017.10.012.
   PubMed Web of Science ®Google Scholar
• Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000;243:147–154. doi:10.1016/s0022-1759(00)00231-3.
   PubMed Web of Science ®Google Scholar
• Verhoeyen E, Costa C, Cosset F-L. Lentiviral vector gene transfer into human T cells. Methods Mol Biol. 2009;506:97–114. doi:10.1007/978-1-59745-409-4_8.
   PubMedGoogle Scholar
• Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72:8463–8471.
   PubMed Web of Science ®Google Scholar
• Salter AI, Ivey RG, Kennedy JJ, Voillet V, Rajan A, Alderman EJ, Voytovich UJ, Lin C, Sommermeyer D, Liu L, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11.
   Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–590. doi:10.1038/nm.3838.
   PubMed Web of Science ®Google Scholar
• Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380–390. doi:10.1016/j.immuni.2016.01.021.
   PubMed Web of Science ®Google Scholar
• Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261–2271. doi:10.1182/blood-2007-12-128843.
   PubMed Web of Science ®Google Scholar
• Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16:1245–1256. doi:10.1016/j.bbmt.2010.03.014.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106–6115. doi:10.1158/1078-0432.CCR-06-1183.
   PubMed Web of Science ®Google Scholar
• Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF, MacEwen EG. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc. 1994;205:1722–1728.
   PubMed Web of Science ®Google Scholar
• Jagielski D, Lechowski R, Hoffmann-Jagielska M, Winiarczyk S. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998–2000). J Vet Med Ser A. 2002;49:419–424.
   PubMedGoogle Scholar
• Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S. Overcoming the immunosuppressive tumor microenvironment of hodgkin lymphoma using chimeric antigen receptor T cells. Cancer Discov. 2017;7:1154–1167. doi:10.1158/2159-8290.CD-16-0850.
   PubMed Web of Science ®Google Scholar
• Busch DH, Fräßle SP, Sommermeyer D, Buchholz VR, Riddell SR. Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol. 2016;28:28–34. doi:10.1016/j.smim.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O’Connor RS, Hwang W-T, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563–571. doi:10.1038/s41591-018-0010-1.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290–1297. doi:10.1038/nm.2446.
   PubMed Web of Science ®Google Scholar
• Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, Bondanza A, Bordignon C, Peccatori J, Ciceri F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121:573–584. doi:10.1182/blood-2012-05-431718.
   PubMed Web of Science ®Google Scholar
• Ghassemi S, Nunez-Cruz S, O’Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, et al. Reducing ex vivo culture improves the antileukemic activity of Chimeric Antigen Receptor (CAR) T cells. Cancer Immunol Res. 2018;6:1100–1109. doi:10.1158/2326-6066.CIR-17-0405.
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25. doi:10.1016/j.coi.2014.01.004.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295. doi:10.1158/2159-8290.CD-15-1020.
   PubMed Web of Science ®Google Scholar
• Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504–1506. doi:10.1038/s41591-018-0146-z.
   PubMed Web of Science ®Google Scholar
• Shah NN, Stetler-Stevenson M, Yuan CM, Shalabi H, Yates B, Delbrook C, Pico-Knijnenburg I, Simons E, Jerchel I, Wawer A, et al. Minimal residual disease negative complete remissions following anti-CD22 Chimeric Antigen Receptor (CAR) in children and young adults with relapsed/refractory Acute Lymphoblastic Leukemia (ALL). Blood. 2016;128: 650–650. doi:10.1182/blood-2016-02-701029.
   Web of Science ®Google Scholar
• Zah E, Lin M-Y, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4:498–508. doi:10.1158/2326-6066.CIR-15-0231.
   PubMed Web of Science ®Google Scholar
• Duman BB, Sahin B, Ergin M, Guvenc B. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature. Med Oncol. 2012;29:1223–1226. doi:10.1007/s12032-011-9955-3.
   PubMed Web of Science ®Google Scholar
• Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Dartigeas C, et al. New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Exp Hematol Oncol. 2015;5:7. doi:10.1186/s40164-016-0036-3.
   PubMedGoogle Scholar